FDA
-
-
-
-
-
-
-
Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease
-
-
-
-
-
-
-
Sol-Gel Announces Reverse Share Split
-
-
-
-
-
-
-
Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
-
-
-
-
-
-
-
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
-
-
-
-
-
-
-
Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610
-
-
-
-
-
-
-
Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Sol Gel Technologies Ltd. (SLGL) PT Raised to $22 at H.C. Wainwright
-
323,582 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

